Alignment Healthcare Inc (ALHC) concluded trading on Thursday at a closing price of $15.25, with 3.58 million shares of worth about $54.61 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 55.45% during that period and on March 06, 2025 the price saw a loss of about -3.54%. Currently the company’s common shares owned by public are about 191.78M shares, out of which, 109.86M shares are available for trading.
Stock saw a price change of 13.21% in past 5 days and over the past one month there was a price change of -1.36%. Year-to-date (YTD), ALHC shares are showing a performance of 35.56% which increased to 182.41% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.46 but also hit the highest price of $16.25 during that period. The average intraday trading volume for Alignment Healthcare Inc shares is 1.88 million. The stock is currently trading 5.99% above its 20-day simple moving average (SMA20), while that difference is up 11.17% for SMA50 and it goes to 39.47% higher than SMA200.
Alignment Healthcare Inc (NASDAQ: ALHC) currently have 191.78M outstanding shares and institutions hold larger chunk of about 56.46% of that.
The stock has a current market capitalization of $2.93B and its 3Y-monthly beta is at 1.48. It has posted earnings per share of -$0.67 in the same period. It has a debt-to-equity ratio of 3.39. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ALHC, volatility over the week remained 6.36% while standing at 4.93% over the month.
Stock’s fiscal year EPS is expected to rise by 39.95% while it is estimated to increase by 48.03% in next year. EPS is likely to grow at an annualized rate of 48.16% for next 5-years, compared to annual growth of -22.95% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Stephens on December 03, 2024 offering an Overweight rating for the stock and assigned a target price range of between $13 and $17 to it. On May 30, 2024, BofA Securities Upgrade their recommendations, while on May 30, 2024, Robert W. Baird Initiated their ratings for the stock with a price target of $10. Stock get an Overweight rating from Piper Sandler on May 08, 2024.
